Back to news

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Business Wire•17/11/2026•09:04 ET
1

Key Highlights

  • ➤60 mg remlifanserin narrowly missed primary endpoint, improving SAPS-H+D by 2.2 points versus placebo
  • ➤60 mg remlifanserin achieved nominal significance on CGI-S-ADP, with p=0.0077
  • ➤Week 6 CGI-I-ADP improvement reached 44.0% with 60 mg versus 31.8% placebo
  • ➤Week 6 NPI/NPI-NH psychosis change was −7.3 versus −5.9 for placebo
  • ➤Acadia continues Phase 3 RADIANT development for Alzheimer’s disease psychosis

Expert Statements

Sanjeev Pathak, M.D., Senior Vice President, Head of Clinical Development at Acadia Pharmaceuticals

“These new analyses strengthen the evidence of a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis and timepoints. The observed dose-response pattern, together with new insights into the relationship between baseline psychosis severity and estimated treatment effect, further reinforces our confidence in the activity of remlifanserin as we continue Phase 3 development.”

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

− New analyses show a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis, with larger estimated treatment effects with increasing baseline psychosis severity

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in